Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: Insights from the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)

Journal of the American College of Cardiology

Volumn 63, Issue 11, 2014, Pages 1082-1087

  Flaker, Greg ^a   Lopes, Renato D ^b   Al Khatib, Sana M ^b   Hermosillo, Antonio G ^c   Hohnloser, Stefan H ^d   Tinga, Brian ^b   Zhu, Jun ^e   Mohan, Puneet ^f   Garcia, David ^g   Bartunek, Jozef ^h   Vinereanu, Dragos ⁱ   Husted, Steen ^j   Harjola, Veli Pekka ^k   Rosenqvist, Marten ^l   Alexander, John H ^b   Granger, Christopher B ^b  

^a University of Missouri   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^d GOETHE UNIVERSITY   (Germany)

^e FUWAI HOSPITAL   (China)

^f BRISTOL MYERS SQUIBB   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h CARDIOVASCULAR CENTER   (Belgium)

ⁱ CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^l KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

atrial fibrillation; cardioversion; factor Xa inhibitor; thromboembolic events; vitamin K antagonist

Indexed keywords

APIXABAN; WARFARIN;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOEMBOLISM; ADULT; ANTICOAGULATION; CONTROLLED STUDY; FOLLOW UP; RISK ASSESSMENT; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT DURATION;

ATRIAL FIBRILLATION; CARDIOVERSION; FACTOR XA INHIBITOR; THROMBOEMBOLIC EVENTS; VITAMIN K ANTAGONIST;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SAFETY; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 84896506763     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.09.062     Document Type: Article

References (19)

1. B. Lown, M.G. Perlroth, S. Kaidbey, T. Abe, and D.E. Harken "Cardioversion" of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients N Engl J Med 269 1963 325 331
2. J.J. Morris Jr., Y. Kong, W.C. North, and H.D. McIntosh Experience with "cardioversion" of atrial fibrillation and flutter Am J Cardiol 14 1964 94 100
3. L. Resnkov, and L. McDonald Complications in 220 patients with cardiac dysrhythmias treated by phased director current shock, and indications for electroconversion Br Heart J 29 1964 926 936
4. B. Lown Electrical reversion of cardiac arrhythmias Br Heart J 29 1967 469 489
5. C.J. Bjerkelund, and O.M. Orning The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation Am J Cardiol 23 1969 208 216
6. D.M. Weinberg, and J. Mancini Anticoagulation for cardioversion of atrial fibrillation Am J Cardiol 63 1989 745 746
7. P. Peterson, and J. Godtfredsen Embolic complications in paroxysmal atrial fibrillation Stroke 17 1986 622 626
8. J. Camm, P. Kirchhof, and G. Lip et al. Guidelines for the management of atrial fibrillation Eur Heart J 31 2010 2369 2429
9. R. Nagarakanti, M. Ezekowitz, and J. Oldgren et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2011 131 136
10. C. Granger, J. Alexander, and J. McMurray et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl Med 365 2011 981 992
11. R. Lopes, J. Alexander, and S. Al-Khatib et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 2010 331 339
12. S. Schulman, C. Kearon Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
13. A. Laupacis, G. Albers, J. Dalen, M. Dunn, W. Feinberg, and A. Jacobson Antithrombotic therapy in atrial fibrillation Chest 108 1995 352S 359S
14. W.J. Manning, D.E. Leeman, P.J. Gotch, and P.C. Come Pulsed Doppler evaluation of mechanical function after electrical cardioversion of atrial fibrillation J Am Coll Cardiol 13 1989 617 623
15. M. Berger, and P. Schweitzer Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis Am J Cardiol 82 1998 1545 1547
16. S. Botkin, L.S. Dhanekula, and B. Olshansky Outpatient cardioversion of atrial arrhythmias: Efficacy, safety, and costs Am Heart J 145 2003 233 238
17. M.H. Kim, K. Krishnan, S. Jain, and B.F. Decena Time course and frequency of subtherapeutic anticoagulation for newly prescribed warfarin anticoagulation before elective cardioversion of atrial fibrillation or flutter Am J Cardiol 88 2001 1428 1431
18. R. Pisters, R. Nieuwlaat, and M.H. Prins et al. Clinical correlates of immediate success and outcome at 1 year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey Europace 14 2012 666 674
19. J. Dahlin, P. Svendsen, and N. Gadsbøll Poor maintenance of sinus rhythm after electrical cardioversion of patients with atrial fibrillation or flutter: a 5-year follow-up of 268 consecutive patients Scand Cardiovasc J 37 2003 324 328